FDA Adverse Event Malfunction Summary report: N

SIMPLEXA FLU A/B AND RSV DIRECT ASSAY

MDR report key: 4379440 · Received December 29, 2014

Report

Report Number
2023365-2014-00045
Event Type
Malfunction
Date Received
December 29, 2014
Date of Event
January 28, 2014
Report Date
January 28, 2014
Manufacturer
FOCUS DIAGNOSTICS, INC.
Product Code
OCC
PMA / PMN Number
K120413
Removal / Correction Number
Z-1144-2014
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

THE CUSTOMER REPORTED 3 FAILURES THAT OCCURRED WITH TWO LOTS. THEY DID NOT IDENTIFY WHICH OF THE TWO LOTS WERE INVOLVED WITH THE THIRD FAILURE. THE INVESTIGATION OF THE SIMPLEXA FLU A/B AND RSV DIRECT KIT (MOL2650) SUGGESTED THAT THE ROOT CAUSE FOR THE OCCURRENCE OF FALSE POSITIVES (AND SUB-AMPLIFICATIONS) WERE DUE TO THE LOT TO LOT VARIABILITY OF THE SCORPION PRIMERS. TO MITIGATE THE OCCURRENCE OF FALSE POSITIVES (AND SUB-AMPLIFICATIONS), FOCUS DX REPLACED THE RECOMBINANT TAQ POLYMERASE USED IN THE MOL2651 REACTION MIX WITH HOT-START TAQ POLYMERASE AND REDUCED PRODUCTION TIME FOLLOWING BULK MOL2651 FORMULATION TO 2 HOURS. ADDITIONALLY, FOCUS DX NOW EMPLOYS MORE EXTENSIVE TESTING WITH NO TEMPLATE CONTROL (NTC) IN THE QC KIT RELEASE CRITERIA. THESE CORRECTIVE AND PREVENTATIVE ACTIONS ARE EFFECTIVE IN MITIGATING THE EFFECTS POSED BY THE POTENTIAL LOT TO LOT VARIABILITY OF THE SCORPIONS. (B)(4).

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT THEY OBSERVED THREE FLU B POSITIVE (FLU A AND RSV NEGATIVE) RESULTS WHICH WERE NEGATIVE ON THE SHELL VIAL TESTS. THE LAB REPORTED THE RESULTS TO THE DOCTOR. THIS MDR IS BEING SUBMITTED FOR THE THIRD OF THREE RESULTS REPORTED TO THE DOCTOR. A VOLUNTARY RECALL HAS BEEN PERFORMED RELATED TO THE REPORTED LOT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
854679 SIMPLEXA FLU A/B AND RSV DIRECT ASSAY IN-VITRO-DIAGNOSTIC TEST, INFLUENZA OCC FOCUS DIAGNOSTICS, INC. MOL2650 UNK

Patients

Seq Age Sex Outcome Treatment
1 UNK